Target intelligence / Profile preview

Nicotinic acetylcholine receptor α7 subtype (α7 nAChR)

Target
α7 nAChR
Molecular classification
Ligand-gated ion channel, Cys-loop receptor superfamily, Receptor (neurotransmitter receptor)
01

Overview

The nicotinic acetylcholine receptor α7 subtype is a homopentameric, ligand-gated ion channel embedded in neuronal and immune cell membranes, composed entirely of α7 subunits. When activated by endogenous acetylcholine or exogenous agonists like nicotine, it opens to allow influx of cations—particularly Ca^2+—rapidly altering cell excitability and downstream signaling. This receptor plays major roles in cognition, neuroprotection, cholinergic modulation of inflammation, and is implicated in memory, learning, and several disease processes including neurodegeneration, schizophrenia, inflammation, cardiovascular disease, and cancer. Its pharmacological targeting has therapeutic relevance but is confounded by issues of rapid desensitization and cell-specific effects.

Other names
alpha-7 nicotinic receptorα7 receptoralpha7 nAChRCHRNA7 (gene name in humans)alpha7 nicotinic acetylcholine receptor
02

Mechanism of action

Agonists: Bind to the receptor, causing channel opening and allowing Ca^2+ (and other cations) to flow in, leading to neuronal excitation or immune modulation. Antagonists: Occupy the ligand binding site, preventing activation and channel opening. Positive allosteric modulators: Enhance the receptor response to agonists, increasing channel open probability or conductance.

03

Biological functions

Signal transduction (by mediating rapid synaptic transmission)Modulation of neuronal excitabilityCholinergic anti-inflammatory pathway (immune response)Memory and learningNeurogenesis (generation of neurons)
04

Disease associations

Neurodegenerative disease (e.g., Alzheimer's disease)Schizophrenia (cognitive dysfunction)Inflammation (especially in sepsis and stroke)Myocardial infarctionCancer (proliferation and metastasis)AtherosclerosisOther (smoking cessation/addiction)
05

Safety considerations

Rapid desensitization, which may limit sustained drug effectsHigh Ca^2+ permeability, potentially contributing to excitotoxicity under pathological conditionsPotential pro-tumorigenic effects in some cancers (due to promotion of proliferation/metastasis)Drug interactions leading to adverse CNS or cardiovascular effects
06

Interacting drugs

Nicotine (agonist)

4 more in the full profile.

07

Biomarkers

CHRNA7 gene expression levels (used in CNS and inflammatory disorders research)α7-nAChR density (by PET or other neuroimaging, in neurodegenerative disease and schizophrenia)

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor α7 subtype (α7 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor α7 subtype (α7 nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call